Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.66 Million CHF | -89.39% |
| 2022 | 34.39 Million CHF | 5.09% |
| 2021 | 32.72 Million CHF | 44.39% |
| 2020 | 22.66 Million CHF | -10.84% |
| 2019 | 25.41 Million CHF | 0.36% |
| 2018 | 25.32 Million CHF | -33.0% |
| 2017 | 37.8 Million CHF | -6.96% |
| 2016 | 40.63 Million CHF | 11.07% |
| 2015 | 36.58 Million CHF | 277.38% |
| 2014 | 9.69 Million CHF | 31.85% |
| 2013 | 7.35 Million CHF | 48.02% |
| 2012 | 4.96 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 6.56 Million CHF | -83.19% |
| 2023 Q4 | -41.92 Million CHF | -421.52% |
| 2023 Q3 | 13.03 Million CHF | 98.63% |
| 2023 FY | 104.15 Million CHF | 202.85% |
| 2023 Q1 | 39.03 Million CHF | 505.63% |
| 2022 FY | 34.39 Million CHF | 5.09% |
| 2022 Q3 | 6.86 Million CHF | -14.46% |
| 2022 Q4 | 6.44 Million CHF | -6.05% |
| 2022 Q2 | 8.02 Million CHF | -41.48% |
| 2022 Q1 | 13.7 Million CHF | 54.31% |
| 2021 Q1 | 9.33 Million CHF | 40.47% |
| 2021 Q2 | 7.44 Million CHF | -20.25% |
| 2021 FY | 32.72 Million CHF | 44.39% |
| 2021 Q3 | 6.24 Million CHF | -16.1% |
| 2021 Q4 | 8.88 Million CHF | 42.17% |
| 2020 Q2 | 8.34 Million CHF | 27.97% |
| 2020 Q4 | 6.64 Million CHF | -1.96% |
| 2020 Q1 | 6.51 Million CHF | -26.42% |
| 2020 Q3 | 6.78 Million CHF | -18.73% |
| 2020 FY | 22.66 Million CHF | -10.84% |
| 2019 Q4 | 8.86 Million CHF | 36.14% |
| 2019 Q3 | 6.5 Million CHF | -26.1% |
| 2019 Q2 | 8.8 Million CHF | 32.38% |
| 2019 Q1 | 6.65 Million CHF | -19.43% |
| 2019 FY | 25.41 Million CHF | 0.36% |
| 2018 Q2 | 8.28 Million CHF | 0.0% |
| 2018 Q3 | 8.25 Million CHF | -0.29% |
| 2018 FY | 25.32 Million CHF | -33.0% |
| 2018 Q4 | 8.25 Million CHF | 0.0% |
| 2018 Q1 | 8.28 Million CHF | -55.25% |
| 2017 Q3 | 18.5 Million CHF | 244.63% |
| 2017 Q4 | 18.5 Million CHF | 0.0% |
| 2017 FY | 37.8 Million CHF | -6.96% |
| 2017 Q2 | 5.36 Million CHF | 0.0% |
| 2017 Q1 | 5.36 Million CHF | 52.25% |
| 2016 Q3 | 3.52 Million CHF | -2.72% |
| 2016 FY | 40.63 Million CHF | 11.07% |
| 2016 Q1 | 3.62 Million CHF | 47.2% |
| 2016 Q2 | 3.62 Million CHF | 0.0% |
| 2016 Q4 | 3.52 Million CHF | 0.0% |
| 2015 Q1 | 3.64 Million CHF | 40.58% |
| 2015 Q4 | 2.46 Million CHF | 0.0% |
| 2015 Q3 | 2.46 Million CHF | -32.4% |
| 2015 FY | 36.58 Million CHF | 277.38% |
| 2015 Q2 | 3.64 Million CHF | 0.0% |
| 2014 FY | 9.69 Million CHF | 31.85% |
| 2014 Q3 | 2.59 Million CHF | 14.9% |
| 2014 Q1 | 2.25 Million CHF | 11.34% |
| 2014 Q2 | 2.25 Million CHF | 0.0% |
| 2014 Q4 | 2.59 Million CHF | 0.0% |
| 2013 Q4 | 2.02 Million CHF | 0.0% |
| 2013 FY | 7.35 Million CHF | 48.02% |
| 2013 Q1 | 1.65 Million CHF | 306.75% |
| 2013 Q2 | 1.65 Million CHF | 0.0% |
| 2013 Q3 | 2.02 Million CHF | 22.76% |
| 2012 Q4 | 405.69 Thousand CHF | 0.0% |
| 2012 Q3 | 405.69 Thousand CHF | 0.0% |
| 2012 FY | 4.96 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -2356.037% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -6583.54% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -3312.443% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -203.396% |
| GB Sciences, Inc. | 1.42 Million USD | -6212.012% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -2533.282% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -40641.328% |
| Skye Bioscience, Inc. | 13.54 Million USD | -561.837% |
| Zenith Capital Corp. | 8.94 Million USD | -902.602% |
| Agentix Corp. | 1.37 Million USD | -6436.345% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1678.301% |
| Biomind Labs Inc. | 994.18 Thousand USD | -8918.741% |
| ContraFect Corporation | 56.88 Million USD | -57.61% |
| CSL Limited | 3.44 Billion USD | 97.4% |
| CytoDyn Inc. | 18.05 Million USD | -396.526% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -4709.276% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -22916.049% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -56.098% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -21480.561% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -5869.955% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -9608.904% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -140.669% |
| SQZ Biotechnologies Company | 85.61 Million USD | -4.723% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -4276.555% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3.316% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -2974.605% |
| Mesoblast Limited | 5.9 Million USD | -1419.192% |
| Marizyme, Inc. | 19.23 Million USD | -366.026% |
| Genus plc | 147.7 Million USD | 39.294% |
| Pharming Group N.V. | 225.49 Million USD | 60.237% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -975.221% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -5963.403% |
| IMV Inc. | 37.7 Million USD | -137.774% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -3113.306% |
| MultiCell Technologies, Inc. | 567.42 USD | -15801722.283% |
| ONE Bio Corp. | 6.44 Million USD | -1291.437% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -4.326% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -262.787% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -4995.404% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1234.661% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 358750.8% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -460.034% |
| Alpha Cognition Inc. | 9.7 Million USD | -823.824% |
| Enzolytics Inc. | 2.17 Million USD | -4013.898% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 94.153% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -8488.381% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -3628.281% |
| Genscript Biotech Corporation | 825.34 Million USD | 89.136% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1723.186% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -34158.232% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -3551.777% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -52178.714% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -4567.73% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -921.304% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1933.78% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -2293.291% |
| Helix BioMedix, Inc. | 1.97 Million USD | -4446.712% |
| EV Biologics, Inc. | 531.96 Thousand USD | -16755.095% |
| Q BioMed Inc. | 3.43 Million USD | -2509.031% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -725.092% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 9.733% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -290.265% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -4785.998% |
| HST Global, Inc. | 140.9 Thousand USD | -63532.538% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -6614.139% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -7870.655% |
| Halberd Corporation | 74.84 Thousand USD | -119702.651% |
| Resverlogix Corp. | 12.71 Million USD | -605.339% |
| Cell Source, Inc. | 4.32 Million USD | -1972.96% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -5577.172% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1126.532% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -514581.706% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -3534.835% |
| Kadimastem Ltd | 2.41 Million USD | -3620.271% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2015.478% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -49305.02% |
| LadRx Corporation | 3.81 Million USD | -2252.246% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -9608.904% |
| Affymax, Inc. | 39.38 Million USD | -127.651% |
| Itoco Inc. | 919.14 Thousand USD | -9655.033% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -7912.752% |
| Mobile Lads Corp. | 554.54 Thousand USD | -16068.668% |
| International Stem Cell Corporation | 5.27 Million USD | -1601.057% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -2247.101% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -356142.6% |
| Qrons Inc. | 643.67 Thousand USD | -13829.766% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -6215.2% |
| SYBLEU INC | 160.87 Thousand USD | -55634.044% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -3920.967% |
| Rebus Holdings, Inc. | 664 Thousand USD | -13403.419% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -4836.503% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -170225.406% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -440654.559% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -147.236% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -5441.576% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -12085.164% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -2782.118% |
| Neutra Corp. | 243.82 Thousand USD | -36673.986% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -413.62% |
| PureTech Health plc | 144.59 Million USD | 37.991% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -337.595% |
| IXICO plc | 4.7 Million USD | -1804.88% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -919.242% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 23.852% |
| CSL Limited | 3.89 Billion USD | 97.697% |
| Cellectis S.A. | 97.32 Million USD | 7.868% |